Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25609164 | 0.78 | GRM5 (0.43) | GRM5NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL31277575 | 0.78 | GRM5 (0.43) | GRM5NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL30661720 | 0.78 | L3MBTL1 (0.49) | NOTUMGRM5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL218007 | 0.78 | L3MBTL1 (0.49) | NOTUMGRM5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29470230 | 0.77 | IDO1 (0.55) | NOTUMIDO1GRM5NPC1TP53 | |
| SCHEMBL3464923 | 0.77 | MEN1 (0.52) | NPC1TSHRRAB9ACYP19A1MAPT | |
| SCHEMBL14802112 | 0.77 | BCHE (0.47) | IDO1GRM5NPC1TSHRRAB9A | |
| SCHEMBL27587153 | 0.77 | GABRG2 (0.53) | IDO1GRM5NPC1TP53TSHR | |
| SCHEMBL27862933 | 0.77 | GABRG2 (0.48) | NOTUMIDO1GRM5KMOMAOB | |
| SCHEMBL16780836 | 0.77 | SLC6A2 (0.53) | NOTUMNPC1TP53RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107177589-A | Modified active high-area carbon for fixing thimet degradation bacteria and preparation method thereof | 光合强化（北京）生物科技有限公司 | 2017-09-19 | — | — | CN | claimed |
| CN-110023304-A | Calpain regulator and its therapeutical uses | 布莱德治疗公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-105992767-B | WNT pathway modulators | 新加坡科技研究局 | 2019-06-21 | — | — | CN | disclosed |
| CN-109790169-A | With the Cyanopyrolidine derivatives as USP30 inhibitor activity | 特殊治疗有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-108200760-A | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | 英安塔制药有限公司 | 2018-06-22 | — | — | CN | disclosed |
| CN-107922319-A | Urea derivative and its purposes | 东丽株式会社 | 2018-04-17 | — | — | CN | disclosed |
| CN-105873928-B | 5 hydroxyl 4 (trifluoromethyl) pyrazolo pyridine derivatives | 第三共株式会社 | 2018-01-23 | — | — | CN | disclosed |
| CN-107177589-A | Modified active high-area carbon for fixing thimet degradation bacteria and preparation method thereof | 光合强化（北京）生物科技有限公司 | 2017-09-19 | — | — | CN | disclosed |
| CN-106074548-A | Monohydrate of azaadamantane derivative | 艾伯维巴哈马有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-103554107-B | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | 艾伯维巴哈马有限公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-101189233-A | Substituted diazabicycloalkane derivatives as ligands for the alpha 7 nicotinic acetylcholine receptor | ABBOTT LAB (US) | 2008-05-28 | — | — | CN | disclosed |
| WO-2008011176-A9 | MYOSIN LIGHT CHAIN KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND RELATED METHODS OF USE | UNIV NORTHWESTERN (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008011176-A2 | MYOSIN LIGHT CHAIN KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND RELATED METHODS OF USE | NORTHWESTERN UNIVERSITY (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021035-A1 | Myosin light chain kinase inhibitor compounds, compostions and related methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-24 | — | — | US | disclosed |
| CN-101087766-A | Pyridazine compounds, compositions, and methods | UNIV NORTHWESTERN (US) | 2007-12-12 | — | — | CN | disclosed |
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
| CN-1930162-A | Tetrahydropyridoindole derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2007-03-14 | — | — | CN | disclosed |
| CN-1675205-A | Novel quinuclidine derivatives and their use | NEUROSEARCH AS (DK) | 2005-09-28 | — | — | CN | disclosed |
| CN-1628109-A | Novel aryl-and heteroaryl-piperazines | NOVO NORDISK AS (DK) | 2005-06-15 | — | — | CN | disclosed |
| CN-1138458-A | Treatment and prevention of prostatic cancer | LILLY CO ELI (US) | 1996-12-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021035-A1 | Myosin light chain kinase inhibitor compounds, compostions and related methods of use | MYLK, MYLK3, MYLK2 | NOTUM 2564/4885IDO1 1695/4885GRM5 2197/4885 |
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | CYP3A5, CYP3A43, CCR5 | NOTUM 1280/4885IDO1 79/4885GRM5 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.